CYP17A1 and prostate carcinoma: Our recent study shows that LRH-1 displays an increased expression pattern in clinical CRPC tissues, CRPC xenograft models, and also abiraterone-treated CRPC tumors, and its overexpression can promote both in vitro androgen deprivation-resistant and in vivo castration-resistant growth capacities in AR-positive prostate cancer cells via its direct transactivation of multiple key steroidogenic enzyme genes (including STAR, CYP11A1, HSD3B2, CYP17A1) and enhanced intratumoral de novo production of androgens (T and DHT) in a CYP17A1-dependent manner.